🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tucatinib added to TDM1 mostly 2L and 40% CNS+ improved PFS by 2.1m in HER2CLIMB02. Unknown about added to TDXd (standard 2L) but…#1 may be better combo than tuc + cape/H (esp CNS+) and #2 supports COMPASSHER2-RD trial! SABCS

Wonderful piece for patients describing clinical trials and questions to ask!

So excited to add new leaders to the Alliance for Clinical Trials in Oncology Patient Advocate Committee.. Vernal as VC for Health Disparities, Jane as VC for Cancer Control. #advocatesNCTN

🌟It was great to speak with Lisa Carey, MD, ScM, FASCO of UNC Lineberger who discussed upcoming #BreastCancer updates from #ASCO24 ➡️Check out VJOncology.com where we'll be publishing the full interview and more soon... ASCO #ASCO24 #Oncology #BCsm OncoAlert

Agree, but would also caution that we know that ER-low is heterogeneous including a significant minority that are luminal. This is why ASCO /CAP guidelines set the bar for ER and endocrine therapy at <1%. Today’s talk supports that decision but we need to get better assays!

So good to hear this remarkable speech at the ASCO opening meeting - salutary to think about when we doubtless will see endless slides later in the week of drug ‘break throughs’ showing marginal benefits for patients!

#ASCO24—Let’s be impatient for our patients. We have a bottleneck of good science waiting to move into the clinic. If we are to #EndCancerAsWeKnowIt, clinical studies must be more accessible, nimble, inclusive, and designed to answer questions in the populations that need them.

Great synopsis! Key that the “HER2- ultralow” group appeared to benefit similarly, highlighting that immunostains are simply not designed for differentiating HER2 in the lowest registers!

Last night, BCRF's Chief Scientific Officer Dr. Dorraya El-Ashry announced a new BCRF-supported Conquer Cancer, the ASCO Foundation young investigator award in honor of our Founding Scientific Director Dr. Larry Norton. #ASCO24

DESTINYBreast 12 presented by Nancy Lin, MD at #ESMO2024 illustrating clear intracranial activity in HER2+ breast cancer with brain Mets - 72% CNS RR! Simultaneously published Nat. Med.

In this recent Review, @prat_aleix Paolo Tarantino, Ada Waks and co-authors discuss mechanisms of synergy, patient selection and resistance to dual HER2 blockade in patients with HER2-amplified tumours: nature.com/articles/s4157…

Great confirmation of the crucial role of pembrolizumab in early TNBC with a clear OS advantage.

ABIGAIL (in HR+/HER2-) and the second IA of the DETECT-5 trial (in HR+/HER2+) both found no usefulness of induction chemo prior to starting an ET-based approach, calling into question a common practice. #ESMO2024 OncoAlert

Absolute benefit about 5% including node-negative. Important update as this drug moves towards adjuvant approval.

Compelling evidence for this new SERD, and even more when combined with abemaciclib, including those with prior CDK4/6i.

PRO-B presentation - web-based patient-reported symptom management via app and alerts resulted not just in clinically meaningful fatigue improvement AND 29% better OS in MBC. If it was a drug it would be a blockbuster! #SABCS24 #bcsm OncoAlert

SERENA-6: ctDNA guided approach to switching from AI to camizestrant upon development of ESR1m in combo with cdk4/6i demonstrates improvement in PFS! PFS2 + OS immature Could be a paradigm shift + could introduce ctDNA monitoring into practice astrazeneca.com/media-centre/p…

Standing ovation at ⁦ASCO⁩ for the Challenge Trial. Take a look at this comparison of the magnitude of the exercise effect from Challenge versus multiple drug effects.

TBCRC 040 (PREDICT-DNA trial): Dr. Natasha Hunter presents - -HER2+ or TN pts with MRD assay after NAT and pre surgery -in TNBC, ctDNA MRD status distinguished between those with RD who had excellent vs poor prognosis Heather Parsons Translational Breast Cancer Research Consortium Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Ben Ho Park

In oncology, we don’t usually love overlapping Kaplan-Meier curves. Except that sometimes we really do. Thanks to NSABP-B51, countless pts will be spared the toxicity of nodal irradiation, and many will live free from a permanent lymph edema that would have impacted their lives.